

thrombin (catalytically active). Thrombin, in turn, catalyzes the activation of fibrinogen as well as the activation of platelets (145). In other words, thrombin activates two branches of the blood-clotting cascade (fibrinogen, platelets). The result is a blood clot, which takes the form of a network of crosslinked fibrin, where platelets are crosslinked to the fibrin.

4. Chronic Myeloid Leukemia

In the United States there are nearly 5000 new cases of CML per year (146). CML is a potentially fatal stem cell cancer that accounts for about 14% of all leukemias (147). More than 80% of patients complain of fatigue, regardless of the phase of CML. About 40% of these patients go to their primary care physicians for something unrelated, and in the process it is determined that their blood cell count is abnormally high. Jamieson et al. (148)

outlined the events leading to the immortalization of cancer cells in the myeloid leukemias, including CML.

Imatinib is used to treat newly diagnosed cases of CML. Where imatinib does not work, nilotinib or dasatinib, which are also tyrosine kinase inhibitors, can be used (149,150,151). As mentioned above, imatinib inhibits BCR-ABL tyrosine kinase.

The criteria for determining response to treatment include hematologic assessments and bone marrow cytogenetics (152), as well as time to treatment failure and PFS (153). Talpaz et al. (154) provide details on measuring hematologic and bone marrow cytogenetic responses during treatment of CML. Hughes and Branford (155) and Baccarani et al. (156) provide further information on using cytogenetics to measure response rates during treatment of CML.

¹⁴⁵Brody T. Nutritional biochemistry. 2nd ed. San Diego, CA: Academic Press; 1999. pp. 524–39.

¹⁴⁶National Cancer Institute. What you need to know about leukemia. NIH publication no.08-3775; 2008 (55 pp.).

¹⁴⁷Sessions J. Chronic myeloid leukemia in 2007. *J. Manage. Care Pharm.* 2007;13(8 Suppl. A):4–7.

¹⁴⁸Jamieson CH, Weissman IL, Passegué E. Chronic versus acute myelogenous leukemia: a question of self-renewal. *Cancer Cell.* 2004;6:531–3.

¹⁴⁹Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. *J. Hematol. Oncol.* 2010;3:47.

¹⁵⁰Terasawa T, Dahabreh I, Trikalinos TA. BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. *PLoS Curr.* 2010;2:RRN1204.

¹⁵¹Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. *J. Clin. Oncol.* 2009;27:6041–51.

¹⁵²Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. *J. Clin. Oncol.* 2008;26:3204–12.

¹⁵³Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. *Blood* 2007;109:5143–50.

¹⁵⁴Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. *New Engl. J. Med.* 2006;354:2531–41.

¹⁵⁵Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. *Hematol. Am. Soc. Hematol. Educ. Program* 2009:477–487.

¹⁵⁶Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood* 2006;108:1809–20.